Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + GEMOX ± IBI305 in Advanced Intrahepatic Cholangiocarcinoma
NCT05251662Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in intrahepatic cholangiocarcinoma (ICC) (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall Response Rate at 90 days. Status: unknown.
02
Drugs
sintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05251662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251662.